Skip to main
LIVN
LIVN logo

Livanova (LIVN) Stock Forecast & Price Target

Livanova (LIVN) Analyst Ratings

Based on 13 analyst ratings
Buy
Strong Buy 38%
Buy 31%
Hold 31%
Sell 0%
Strong Sell 0%

Bulls say

LivaNova has demonstrated a positive financial trajectory, evident in a mid-single-digit revenue growth of 6.7% for 2024, with expectations of organic growth in the cardiopulmonary segment of 7.0-8.0% for 2025. The company's gross margin improved by 160 basis points year-over-year, alongside an operating margin increase of 180 basis points, driven by gross margin expansion and effective management of selling, general, and administrative expenses. Furthermore, LivaNova anticipates a strengthening in revenue as elective procedures rebound post-COVID-19, combined with ongoing improvements in production capacity for oxygenators projected at an additional 10-15% increase in 2025.

Bears say

LivaNova's recent performance indicates a concerning trend, with neuromodulation sales experiencing a significant slowdown, growing only 1.0% to $137.6 million, which fell short of expectations and represents a decline from previous quarters' growth rates. Additionally, despite an 11.2% increase in cardiopulmonary sales to $181.7 million, this growth rate has also diminished from earlier periods, suggesting potential challenges in sustaining momentum in both core business segments. The company's guidance for revenue growth trending towards low-single digits, combined with operating margin contraction and underperformance in earnings relative to consensus expectations, reinforces a negative outlook on its future financial prospects.

Livanova (LIVN) has been analyzed by 13 analysts, with a consensus rating of Buy. 38% of analysts recommend a Strong Buy, 31% recommend Buy, 31% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Livanova and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Livanova (LIVN) Forecast

Analysts have given Livanova (LIVN) a Buy based on their latest research and market trends.

According to 13 analysts, Livanova (LIVN) has a Buy consensus rating as of Aug 25, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $68.46, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $68.46, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Livanova (LIVN)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.